Morgan Stanley has taken a significant step in the structured investment market by filing a free writing prospectus (FWP) related to its new securities linked to KLA Corporation's common stock. This filing, dated November 12, 2026, is part of the company's strategy to expand its offerings in the competitive landscape of security brokers and dealers.
The filing outlines the terms of the securities, which are designed to provide investors with contingent fixed returns while also carrying a risk of principal loss. This dual nature of the investment reflects Morgan Stanley's commitment to offering innovative financial products that cater to diverse investor needs.
Background
Morgan Stanley, a prominent player in the financial services industry, operates under the Standard Industrial Classification (SIC) code 6211, which pertains to Security Brokers, Dealers & Flotation Companies. The company is listed on the New York Stock Exchange (NYSE) with multiple tickers, including MS, MS-PK, and others. As a large accelerated filer, Morgan Stanley has a significant presence in the financial markets, providing a range of services from investment banking to wealth management.
What the Filing Says
The filing details a structured investment product that is fully and unconditionally guaranteed by Morgan Stanley. It specifies that the securities are linked to the common stock of KLA Corporation and are set to mature on November 24, 2027. The prospectus highlights that the face amount of each security is $1,000, with a minimum contingent fixed return of at least 16% of the face amount, potentially providing $160 per security.
Additionally, the filing states, "If the ending price is greater than or equal to the threshold price, you will receive $1,000 plus the contingent fixed return." However, it also warns that if the ending price is less than the threshold price, investors may lose more than 50% of their investment.
Impact
This filing may affect a range of stakeholders, including institutional and retail investors looking for structured investment opportunities. It also positions Morgan Stanley in direct competition with other financial institutions, particularly Wells Fargo Securities, which is mentioned as an agent for this offering. The structured nature of these investments may attract investors seeking higher returns, albeit with increased risk.
What's Next
The filing does not specify what happens next, but investors are encouraged to review the accompanying amended preliminary pricing supplement for further details. This document will provide additional insights into the terms, risks, and potential returns associated with the investment.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










